Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study

This study was conducted to analyze if the combination of Bevacizumab with standard chemotherapy increases postoperative morbidity and mortality after resection of colorectal liver metastases as compared with resection after chemotherapy alone. Parameters contributing to an increased morbidity were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of surgery 2010-07, Vol.252 (1), p.124-130
Hauptverfasser: TAMANDL, Dietmar, GRUENBERGER, Birgit, KLINGER, Markus, HERBERGER, Beata, KACZIREK, Klaus, FLEISCHMANN, Edith, GRUENBERGER, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 130
container_issue 1
container_start_page 124
container_title Annals of surgery
container_volume 252
creator TAMANDL, Dietmar
GRUENBERGER, Birgit
KLINGER, Markus
HERBERGER, Beata
KACZIREK, Klaus
FLEISCHMANN, Edith
GRUENBERGER, Thomas
description This study was conducted to analyze if the combination of Bevacizumab with standard chemotherapy increases postoperative morbidity and mortality after resection of colorectal liver metastases as compared with resection after chemotherapy alone. Parameters contributing to an increased morbidity were evaluated. Most patients referred for colorectal liver metastases are treated with neoadjuvant chemotherapy before hepatic surgery. Targeted agents like the vascular endothelial growth factor-antagonist Bevacizumab are increasingly added to standard therapy to prolong survival; however, little is known about the consequences of this policy in the perioperative period. One hundred-two patients treated between 2005 and 2009, who received neoadjuvant chemotherapy combined with Bevacizumab (CHT + B) were identified. A cohort of 112 patients treated without chemotherapy alone before resection served as the control group (CHT). Complications were graded within an established staging system and the therapeutic consequences were laid down. Uni- and multivariate analysis of factors contributing to postoperative complications in the CHT + B group was performed using a logistic regression model. Postoperative complications occurred in 45 (44%, CHT + B) and 38 (34%, CHT) patients, respectively (P = 0.216). The incidence of severe complications requiring surgical or radiologic intervention or leading to organ failure was 10.8% in the CHT + B group and 7.1% in the CHT group (P = 0.350). Increased age, low serum albumin, resection of more than 3 liver segments and synchronous bowel procedures requiring an anastomosis were associated with an increased morbidity rate in the multivariate regression analysis. No patient died in either group. The addition of Bevacizumab to standard chemotherapy before resection of colorectal liver metastases does not seem to increase postoperative morbidity. Caution should be given to extended resections >3 liver segments and synchronous bowel anastomoses.
doi_str_mv 10.1097/SLA.0b013e3181deb67f
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733403899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733403899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-f21ca817ac1be8817a936ed0b577e28d8b74437690360299fc8fc134f0e0698a3</originalsourceid><addsrcrecordid>eNpdkE1v1DAURS1ERYfCP0DIG8Qq5dnOxDa7IeKj0qhFDKyjF_uZpkriwU5Gmv56UnUAidW7i3Pvkw5jrwRcCrD63W67uYQWhCIljPDUVjo8YSuxlqYQooSnbAUAqiitkufsec53AKI0oJ-xcwnrSlZCrdhh2x0o8W-UyU1dHJc0YDdmjnyHgfjXFB35ORHfhGkBrymiv5sPOE68vqUhTreUcH_kV6PrZ9-NP_kHOqDr7ucB2_d8w2vMVNRxnFLse_J8N83--IKdBewzvTzdC_bj08fv9Zdie_P5qt5sCyfNeiqCFA6N0OhES-YhWFWRh3atNUnjTavLUunKgqpAWhucCU6oMgBBZQ2qC_b2cXef4q-Z8tQMXXbU9zhSnHOjlSpBGWsXsnwkXYo5JwrNPnUDpmMjoHkQ3izCm_-FL7XXpwdzO5D_W_pjeAHenADMDvuQcHRd_sdJW0m9jP4GTnWK7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733403899</pqid></control><display><type>article</type><title>Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>PubMed Central</source><creator>TAMANDL, Dietmar ; GRUENBERGER, Birgit ; KLINGER, Markus ; HERBERGER, Beata ; KACZIREK, Klaus ; FLEISCHMANN, Edith ; GRUENBERGER, Thomas</creator><creatorcontrib>TAMANDL, Dietmar ; GRUENBERGER, Birgit ; KLINGER, Markus ; HERBERGER, Beata ; KACZIREK, Klaus ; FLEISCHMANN, Edith ; GRUENBERGER, Thomas</creatorcontrib><description>This study was conducted to analyze if the combination of Bevacizumab with standard chemotherapy increases postoperative morbidity and mortality after resection of colorectal liver metastases as compared with resection after chemotherapy alone. Parameters contributing to an increased morbidity were evaluated. Most patients referred for colorectal liver metastases are treated with neoadjuvant chemotherapy before hepatic surgery. Targeted agents like the vascular endothelial growth factor-antagonist Bevacizumab are increasingly added to standard therapy to prolong survival; however, little is known about the consequences of this policy in the perioperative period. One hundred-two patients treated between 2005 and 2009, who received neoadjuvant chemotherapy combined with Bevacizumab (CHT + B) were identified. A cohort of 112 patients treated without chemotherapy alone before resection served as the control group (CHT). Complications were graded within an established staging system and the therapeutic consequences were laid down. Uni- and multivariate analysis of factors contributing to postoperative complications in the CHT + B group was performed using a logistic regression model. Postoperative complications occurred in 45 (44%, CHT + B) and 38 (34%, CHT) patients, respectively (P = 0.216). The incidence of severe complications requiring surgical or radiologic intervention or leading to organ failure was 10.8% in the CHT + B group and 7.1% in the CHT group (P = 0.350). Increased age, low serum albumin, resection of more than 3 liver segments and synchronous bowel procedures requiring an anastomosis were associated with an increased morbidity rate in the multivariate regression analysis. No patient died in either group. The addition of Bevacizumab to standard chemotherapy before resection of colorectal liver metastases does not seem to increase postoperative morbidity. Caution should be given to extended resections &gt;3 liver segments and synchronous bowel anastomoses.</description><identifier>ISSN: 0003-4932</identifier><identifier>EISSN: 1528-1140</identifier><identifier>DOI: 10.1097/SLA.0b013e3181deb67f</identifier><identifier>PMID: 20562613</identifier><identifier>CODEN: ANSUA5</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - therapeutic use ; Bevacizumab ; Biological and medical sciences ; Case-Control Studies ; Colorectal Neoplasms - pathology ; Female ; General aspects ; Hepatectomy ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - secondary ; Liver Neoplasms - therapy ; Liver, biliary tract, pancreas, portal circulation, spleen ; Male ; Medical sciences ; Middle Aged ; Neoadjuvant Therapy ; Postoperative Complications ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the digestive system</subject><ispartof>Annals of surgery, 2010-07, Vol.252 (1), p.124-130</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c285t-f21ca817ac1be8817a936ed0b577e28d8b74437690360299fc8fc134f0e0698a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22962701$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20562613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TAMANDL, Dietmar</creatorcontrib><creatorcontrib>GRUENBERGER, Birgit</creatorcontrib><creatorcontrib>KLINGER, Markus</creatorcontrib><creatorcontrib>HERBERGER, Beata</creatorcontrib><creatorcontrib>KACZIREK, Klaus</creatorcontrib><creatorcontrib>FLEISCHMANN, Edith</creatorcontrib><creatorcontrib>GRUENBERGER, Thomas</creatorcontrib><title>Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study</title><title>Annals of surgery</title><addtitle>Ann Surg</addtitle><description>This study was conducted to analyze if the combination of Bevacizumab with standard chemotherapy increases postoperative morbidity and mortality after resection of colorectal liver metastases as compared with resection after chemotherapy alone. Parameters contributing to an increased morbidity were evaluated. Most patients referred for colorectal liver metastases are treated with neoadjuvant chemotherapy before hepatic surgery. Targeted agents like the vascular endothelial growth factor-antagonist Bevacizumab are increasingly added to standard therapy to prolong survival; however, little is known about the consequences of this policy in the perioperative period. One hundred-two patients treated between 2005 and 2009, who received neoadjuvant chemotherapy combined with Bevacizumab (CHT + B) were identified. A cohort of 112 patients treated without chemotherapy alone before resection served as the control group (CHT). Complications were graded within an established staging system and the therapeutic consequences were laid down. Uni- and multivariate analysis of factors contributing to postoperative complications in the CHT + B group was performed using a logistic regression model. Postoperative complications occurred in 45 (44%, CHT + B) and 38 (34%, CHT) patients, respectively (P = 0.216). The incidence of severe complications requiring surgical or radiologic intervention or leading to organ failure was 10.8% in the CHT + B group and 7.1% in the CHT group (P = 0.350). Increased age, low serum albumin, resection of more than 3 liver segments and synchronous bowel procedures requiring an anastomosis were associated with an increased morbidity rate in the multivariate regression analysis. No patient died in either group. The addition of Bevacizumab to standard chemotherapy before resection of colorectal liver metastases does not seem to increase postoperative morbidity. Caution should be given to extended resections &gt;3 liver segments and synchronous bowel anastomoses.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Female</subject><subject>General aspects</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver, biliary tract, pancreas, portal circulation, spleen</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Postoperative Complications</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the digestive system</subject><issn>0003-4932</issn><issn>1528-1140</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1v1DAURS1ERYfCP0DIG8Qq5dnOxDa7IeKj0qhFDKyjF_uZpkriwU5Gmv56UnUAidW7i3Pvkw5jrwRcCrD63W67uYQWhCIljPDUVjo8YSuxlqYQooSnbAUAqiitkufsec53AKI0oJ-xcwnrSlZCrdhh2x0o8W-UyU1dHJc0YDdmjnyHgfjXFB35ORHfhGkBrymiv5sPOE68vqUhTreUcH_kV6PrZ9-NP_kHOqDr7ucB2_d8w2vMVNRxnFLse_J8N83--IKdBewzvTzdC_bj08fv9Zdie_P5qt5sCyfNeiqCFA6N0OhES-YhWFWRh3atNUnjTavLUunKgqpAWhucCU6oMgBBZQ2qC_b2cXef4q-Z8tQMXXbU9zhSnHOjlSpBGWsXsnwkXYo5JwrNPnUDpmMjoHkQ3izCm_-FL7XXpwdzO5D_W_pjeAHenADMDvuQcHRd_sdJW0m9jP4GTnWK7g</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>TAMANDL, Dietmar</creator><creator>GRUENBERGER, Birgit</creator><creator>KLINGER, Markus</creator><creator>HERBERGER, Beata</creator><creator>KACZIREK, Klaus</creator><creator>FLEISCHMANN, Edith</creator><creator>GRUENBERGER, Thomas</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study</title><author>TAMANDL, Dietmar ; GRUENBERGER, Birgit ; KLINGER, Markus ; HERBERGER, Beata ; KACZIREK, Klaus ; FLEISCHMANN, Edith ; GRUENBERGER, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-f21ca817ac1be8817a936ed0b577e28d8b74437690360299fc8fc134f0e0698a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Female</topic><topic>General aspects</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver, biliary tract, pancreas, portal circulation, spleen</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Postoperative Complications</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the digestive system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TAMANDL, Dietmar</creatorcontrib><creatorcontrib>GRUENBERGER, Birgit</creatorcontrib><creatorcontrib>KLINGER, Markus</creatorcontrib><creatorcontrib>HERBERGER, Beata</creatorcontrib><creatorcontrib>KACZIREK, Klaus</creatorcontrib><creatorcontrib>FLEISCHMANN, Edith</creatorcontrib><creatorcontrib>GRUENBERGER, Thomas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TAMANDL, Dietmar</au><au>GRUENBERGER, Birgit</au><au>KLINGER, Markus</au><au>HERBERGER, Beata</au><au>KACZIREK, Klaus</au><au>FLEISCHMANN, Edith</au><au>GRUENBERGER, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study</atitle><jtitle>Annals of surgery</jtitle><addtitle>Ann Surg</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>252</volume><issue>1</issue><spage>124</spage><epage>130</epage><pages>124-130</pages><issn>0003-4932</issn><eissn>1528-1140</eissn><coden>ANSUA5</coden><abstract>This study was conducted to analyze if the combination of Bevacizumab with standard chemotherapy increases postoperative morbidity and mortality after resection of colorectal liver metastases as compared with resection after chemotherapy alone. Parameters contributing to an increased morbidity were evaluated. Most patients referred for colorectal liver metastases are treated with neoadjuvant chemotherapy before hepatic surgery. Targeted agents like the vascular endothelial growth factor-antagonist Bevacizumab are increasingly added to standard therapy to prolong survival; however, little is known about the consequences of this policy in the perioperative period. One hundred-two patients treated between 2005 and 2009, who received neoadjuvant chemotherapy combined with Bevacizumab (CHT + B) were identified. A cohort of 112 patients treated without chemotherapy alone before resection served as the control group (CHT). Complications were graded within an established staging system and the therapeutic consequences were laid down. Uni- and multivariate analysis of factors contributing to postoperative complications in the CHT + B group was performed using a logistic regression model. Postoperative complications occurred in 45 (44%, CHT + B) and 38 (34%, CHT) patients, respectively (P = 0.216). The incidence of severe complications requiring surgical or radiologic intervention or leading to organ failure was 10.8% in the CHT + B group and 7.1% in the CHT group (P = 0.350). Increased age, low serum albumin, resection of more than 3 liver segments and synchronous bowel procedures requiring an anastomosis were associated with an increased morbidity rate in the multivariate regression analysis. No patient died in either group. The addition of Bevacizumab to standard chemotherapy before resection of colorectal liver metastases does not seem to increase postoperative morbidity. Caution should be given to extended resections &gt;3 liver segments and synchronous bowel anastomoses.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>20562613</pmid><doi>10.1097/SLA.0b013e3181deb67f</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4932
ispartof Annals of surgery, 2010-07, Vol.252 (1), p.124-130
issn 0003-4932
1528-1140
language eng
recordid cdi_proquest_miscellaneous_733403899
source MEDLINE; Journals@Ovid Complete; PubMed Central
subjects Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Bevacizumab
Biological and medical sciences
Case-Control Studies
Colorectal Neoplasms - pathology
Female
General aspects
Hepatectomy
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Liver, biliary tract, pancreas, portal circulation, spleen
Male
Medical sciences
Middle Aged
Neoadjuvant Therapy
Postoperative Complications
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
title Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A23%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20Resection%20Remains%20a%20Safe%20Procedure%20After%20Neoadjuvant%20Chemotherapy%20Including%20Bevacizumab:%20A%20Case-Controlled%20Study&rft.jtitle=Annals%20of%20surgery&rft.au=TAMANDL,%20Dietmar&rft.date=2010-07-01&rft.volume=252&rft.issue=1&rft.spage=124&rft.epage=130&rft.pages=124-130&rft.issn=0003-4932&rft.eissn=1528-1140&rft.coden=ANSUA5&rft_id=info:doi/10.1097/SLA.0b013e3181deb67f&rft_dat=%3Cproquest_cross%3E733403899%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733403899&rft_id=info:pmid/20562613&rfr_iscdi=true